Form 4: CervoMed Director Jeffrey Poulton Granted Stock Options Following Board Election

CervoMed Inc. Director Jeffrey V. Poulton was granted options to purchase 8,100 shares of common stock at an exercise price of $6.52 per share, vesting monthly over one year.

Summary

• Jeffrey V. Poulton, a Director of CervoMed Inc. (CRVO), was granted an option to purchase 8,100 shares of the company's common stock.
• The grant occurred on June 23, 2025, in connection with his election to the Issuer's board of directors at the 2025 Annual Meeting of Stockholders.
• The options were granted under CervoMed's 2025 Equity Incentive Plan, consistent with its non-employee director compensation policy.
• The exercise price for the options is $6.52 per share.
• The options will vest on a monthly basis over a one-year period, in substantially equal 1/12th increments, beginning on June 30, 2025.
• Vesting is contingent upon Mr. Poulton's continued service through the applicable vesting dates.
• The options have an expiration date of June 23, 2035.
• Following this transaction, Mr. Poulton beneficially owns 8,100 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports a standard, expected compensation event for a director, which is generally positive as it aligns interests, but does not contain information that would significantly alter the company's financial outlook or strategic direction.

Positives

• The grant of stock options to Director Jeffrey V. Poulton aligns his financial interests with those of the shareholders, incentivizing long-term performance.
• The compensation is part of a pre-existing 2025 Equity Incentive Plan and non-employee director compensation policy, indicating structured corporate governance.

Future Outlook

The stock options granted to Director Jeffrey V. Poulton will vest monthly over a one-year period, beginning June 30, 2025, subject to his continued service. The options have an expiration date of June 23, 2035.

Industry Context

The grant of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain qualified board members and align their interests with long-term shareholder value. This filing indicates CervoMed Inc. is following standard corporate governance practices for director compensation.

Comparison to Industry Standards

• The grant of stock options to non-employee directors, with a vesting schedule tied to continued service, is a widely accepted and standard compensation practice across publicly traded companies, including those in the biotech sector.
• While specific grant sizes and exercise prices vary by company size, stage, and market conditions, the structure of this grant to Jeffrey V. Poulton aligns with typical industry benchmarks for incentivizing board members. For example, similar equity grants are common at companies like Biogen Inc. or Vertex Pharmaceuticals Inc. for their non-executive directors, though the scale would differ based on market capitalization and compensation philosophy.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. It also represents a dilution potential as options are exercised, though this is a standard part of equity compensation.

Next Steps

• Monthly vesting of the 8,100 stock options will occur over a one-year period, starting June 30, 2025.
• Jeffrey V. Poulton's continued service on the board of directors is required for the options to vest.

Key Dates

Keywords

CervoMed Inc., CRVO, Jeffrey V. Poulton, Stock Option, Equity Incentive Plan, Director Compensation, SEC Form 4, Insider Transaction, Corporate Governance, Equity Grant